Bajaj Healthcare reports Q2 revenue growth of 18.9% and PAT growth of 26.9%
As filed · Bajaj Healthcare Limited has informed the Exchange regarding a press release dated October 17, 2026, titled "Press Release on the financial results of the Company for the quarter ended September 30, 2
What happened
FactBajaj Healthcare reported unaudited Q2 FY27 revenue from operations of Rs. 175.9 Crore, EBITDA of Rs. 32.1 Crore and profit after tax of Rs. 14.1 Crore. Formulations revenue grew ~82% YoY, API exports rose 28.5% YoY, Cenobamate tablet commercialisation began through 8 marketing partners, and the company said it received NCLT approval for the acquisition of GenRx.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
ContradictedGross profit for the quarter stood at INR80.4 crores, up by 16.2% year-on-year compared to INR69.1 crores in Q1 FY26.
Profit after tax from continuing operations stood at about INR13.9 crores, up by 14.1% year-on-year from INR12.2 crores in Q1 last year and broadly remaining stable versus INR13.8 crores in Q4, translating into a PAT margin from continuing operations of 8.4%.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We completed the construction of a plant with the capacity to process approximately 250 MT of opium gum and ab (management committed by FY29)
Evidence
- Bajaj Healthcare Limited has informed the Exchange regarding a press release dated October 17, 2026, titled "Press Release on the financial results of the Company for the quarter ended September 30, 2026".(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The quarter showed broad improvement led by formulations and API exports, with higher margins and PAT growth. Cenobamate commercialisation, the GenRx acquisition approval and the planned peptide facility commissioning could expand the company’s specialty and formulations platform, subject to execution.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%